[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352211-105":59,"doc-detail-352211-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cd200cd200r-as-a-myelooid-immune-checkpoint-in-solid-tumors-mechanisms-context-dependent-functions-and-therapeutic-opportunities","CD200–CD200R as a myeloid immune checkpoint in solid tumors - mechanisms, context-dependent functions, and therapeutic opportunities","","CD200 and its receptor CD200R constitute a myeloid-centered immune checkpoint that normally restrains myeloid activation and limits tissue damage, yet many solid tumors exploit this pathway to suppress antitumor immunity. CD200–CD200R signaling is context-dependent, producing divergent outcomes across cancer models and consistently reducing macrophage, dendritic cell, NK-cell, and CD8+ T-cell activation while impairing phagocytosis and antigen presentation. CD200R1–CD200 is also proposed as a macrophage phagocytosis checkpoint independent of CD47–SIRPa. A context-dependent framework is presented to guide tumor-specific therapies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cd200cd200r-as-a-myelooid-immune-checkpoint-in-solid-tumors-mechanisms-context-dependent-functions-and-therapeutic-opportunities/352211/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cd200cd200r-as-a-myelooid-immune-checkpoint-in-solid-tumors-mechanisms-context-dependent-functions-and-therapeutic-opportunities/352211.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What role does the CD200–CD200R pathway play in normal immunity?","Question",{"text":113,"@type":114},"CD200 and CD200R regulate peripheral immune tolerance and tissue protection during inflammatory responses, restraining myeloid activation to limit tissue damage.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why are CD200–CD200R effects considered context-dependent in solid tumors?",{"text":118,"@type":114},"The pathway can promote immune evasion or suppress protumor inflammation depending on tumor type and model, even within the same cancer category.",{"name":120,"@type":111,"acceptedAnswer":121},"How does CD200R1–CD200 relate to other innate immune checkpoint pathways?",{"text":122,"@type":114},"CD200R1–CD200 has been identified as a macrophage phagocytosis checkpoint functioning independently of the CD47–SIRPa axis.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352211,1790364264,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Review  \nPUBLISHED 18 September 2026 DOI 10.3389/fimmu.2026.1950382  \nOPEN ACCESS  \nEDITED BY  \nGaia Codolo,  \nUniversity of Padua, Italy  \nREVIEWED BY  \nXiang Teng Chen,  \nGuizhou Medical University, China Zhaojuan Yang,  \nShanghai Cancer Institute, China  \n*CORRESPONDENCE  \nSujit Basu  \n [sujit.basu@osumc.edu](sujit.basu@osumc.edu)  \nRECEIVED 28 July 2026  \nREVISED 03 September 2026  \nACCEPTED 07 September 2026  \nPUBLISHED 18 September 2026  \nCITATION  \nSahu MR, Ezhil I, Akkanapally V, Kumar A, Liu J-Q and Basu S (2026) CD200– CD200R as a myeloid immune checkpoint in solid tumors: mechanisms, context-dependent functions, and therapeutic opportunities.  \nFront. Immunol. 17:1950382 .  \ndoi: 10.3389/fimmu.2026.1950382  \nCOPYRIGHT  \n© 2026 Sahu, Ezhil, Akkanapally, Kumar, Liu and Basu. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCD200–CD200R as a myeloid immune checkpoint in solid tumors: mechanisms, contextdependent functions, and therapeutic opportunities  \nManas Ranjan Sahu 1, Inemai Ezhil 1, Venu Akkanapally1, Aman Kumar 1, Jin-Qing Liu 1 and Sujit Basu 1,2,3*  \n1 Department of Pathology, Ohio State University, Columbus, OH, United States, 2 Division of Medical Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH, United States, 3Comprehensive Cancer Center, Ohio State University, Columbus, OH, United States  \nCD200 and its receptor CD200R form a myeloid-centered immune checkpoint that normally restrains myeloid activation and limits tissue damage, but many solid tumors co-opt this pathway to suppress antitumor immunity. CD200–CD200R signaling is highly context-dependent, varying even among models of the same cancer type. In melanoma and breast carcinoma, it can either suppress protumor inﬂammation or promote tumor growth and metastasis depending on the model, whereas in neuroblastoma; glioblastoma and other central nervous system tumors; cutaneous and head and neck squamous cell carcinoma; colorectal cancer; and several endocrine, ovarian, and pancreatic cancers, it consistently suppresses macrophage, dendritic cell, natural killer cell, and CD8+ T-cell activation, impairs phagocytosis and antigen presentation, and drives immunosuppressive inﬁltration. Non-small cell lung cancer and renal cell carcinoma emerge as two additional, less-characterized but clinically important contexts warranting further investigation. CD200R1–CD200 has also recently been identiﬁed as a macrophage phagocytosis checkpoint that functions independently of CD47–SIRPa, placing it within the expanding family of innate immune checkpoints. Rather than treating CD200–CD200R as a universally protumorigenic target, we propose a context-dependent framework—incorporating tumor type, microenvironmental architecture, and dominant myeloid and lymphoid programs—to guide tumor-speciﬁc therapeutic strategies in solid cancers.  \nKEYWORDS  \nCD200, CD200R, solid tumors, therapy, tumor microenvironment  \nIntroduction  \nImmune checkpoint blockade targeting programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has transformed the treatment of several solid tumors; yet most patients either fail to respond or eventually develop disease progression. One major limitation is that these T-celldirected therapies do not adequately address the myeloid-driven immunosuppression that  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \ncharacterizes many tumor microenvironments (1, 2) . This unmet need has driven increasing interest in myeloid immune checkpoints—i","cbCaivT5S7IeLvSe","https://ap.wps.com/l/cbCaivT5S7IeLvSe","pdf",3369038,14,"English","# Introduction\n## Rationale for myeloid immune checkpoints beyond PD-1/PD-L1 and CTLA-4\n## Origins and evolving roles of CD200–CD200R in tolerance and cancer\n## Context-dependent outcomes across solid tumor types","[{\"question\":\"What role does the CD200–CD200R pathway play in normal immunity?\",\"answer\":\"CD200 and CD200R regulate peripheral immune tolerance and tissue protection during inflammatory responses, restraining myeloid activation to limit tissue damage.\"},{\"question\":\"Why are CD200–CD200R effects considered context-dependent in solid tumors?\",\"answer\":\"The pathway can promote immune evasion or suppress protumor inflammation depending on tumor type and model, even within the same cancer category.\"},{\"question\":\"How does CD200R1–CD200 relate to other innate immune checkpoint pathways?\",\"answer\":\"CD200R1–CD200 has been identified as a macrophage phagocytosis checkpoint functioning independently of the CD47–SIRPa axis.\"}]","CD200–CD200R as a myeloid immune checkpoint in solid tumors - mechanisms, context-dependent functions, and therapeutic opportunities | PDF",1790098315,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95426c4de970d2625d52092cc999265b.webp",983,1389,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6308f3bb1f02d6f53163e317608cd08c.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7889d99a8c889ec23eec2649f14accf2.webp",981,1386,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cd5fe91cd0fd7df1b2c5a02499aecdf.webp",980,1385]